Skip to content

The randomized trial about the efficacy of a 2-Day in-Hospital Diabetes Educational Program for prevention of type 2 diabetes (The JOETSU Diabetes Prevention Trial)

The randomized trial about the efficacy of a 2-Day in-Hospital Diabetes Educational Program for prevention of type 2 diabetes (The JOETSU Diabetes Prevention Trial) - The 2-Day in-Hospital Diabetes Educational Program for patients of Impared Glucose Tolerance (The JOETSU Diabetes Prevention Trial)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000000911
Enrollment
500
Registered
2007-11-29
Start date
2003-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impared Glucose Tolerance

Interventions

In the STH (Short Term Hospitalization) group, participants took a 9-lesson curriculum, designed as a clinical course, covering special diet, exercise, and behavior modification to help them change th

Sponsors

Niigata-Rousai Hospital, Joetsu, Japan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: We screened for patients aged between 20 and 70 years, BMI: 20–34 kg/m2, fasting plasma glucose concentration ≥100 mg/dl (5.6 mmol/l), or HbA1c level between 5.2 and 6.4%. The patients were eligible for our study if they had impaired glucose tolerance – defined as plasma glucose concentration ≤ 125 mg/dl (6.9 mmol/l) in the fasting state, and 140 to 199 mg/dl (7.8 to 11.0 mmol/l) two hours after a 75 g oral glucose load, according to the 2003 ADA criteria. In addition, all participants were confirmed to have systolic blood pressure <150mmHg, diastolic blood pressure <100mmHg, total cholesterol <300mg/dl, triglycerides <220mg/dl, and LDL-cholesterol <180mg/dl.

Exclusion criteria

Exclusion criteria: We exclude patients who were diabetes, hypertension, or hyperlipidemia with taking any medication which might affect glycemic control.

Design outcomes

Primary

MeasureTime frame
All participants were seen at 3-month intervals by their physicians. Blood and urine samples were taken for examination. We estimated the incidence of type 2 diabetes.

Secondary

MeasureTime frame
All participants were seen at 3-month intervals by their physicians. Body weight, waist circumference, and blood pressure were measured. We estimated the efficay of our program for changes in serum lipids, body weight, and blood pressure

Countries

Japan

Contacts

Public ContactTetsuya Kawahara

Niigata-Rousai Hospital, Joetsu, Japan Department of Internal Medicine

k-tetsuy@niirou.jp025-543-3123

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026